Pfizer has discontinued the SUN 1170 Phase III study of Sutent (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer. The decision follows a review by the independent Data Monitoring Committee (DMC) that showed a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm. Also, sunitinib did not demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced liver cancer. No new or unexpect...